Comparative Pharmacology
Head-to-head clinical analysis: PHENETRON versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENETRON versus PROMETHAZINE DM.
PHENETRON vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
Adults: 50 mg intramuscularly every 6 hours as needed.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic